通过酶指导的自组合来打击线粒体,以获得有效的免疫性抗瘤疗法
Jingyuan Zhao1, Siyu Tian1, Pengfei Li2
1Clinical Laboratory Center, Central Hospital of Dalian University of Technology, Dalian, People's Republic of China.
International journal of nanomedicine
|November 13, 2025
概括
这项研究引入了PSK,一种新型的类药物,可触发免疫细胞死亡 (ICD),并通过精确向瘤来增强癌症免疫疗法. PSK提供了一种新的癌症治疗策略,具有双重作用的抗瘤效应.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 癌症研究 癌症研究
背景情况:
- 免疫性细胞死亡 (ICD) 通过破坏瘤微环境 (TME) 对癌症免疫疗法至关重要.
- 目前的挑战包括不高效的ICD诱导和与其他抗癌机制的有限协同作用.
- 编程细胞死亡配体1 (PD-L1) 和豆素是瘤细胞和TME的关键标.
研究的目的:
- 开发一种新型的自我组装,PSK,用于精确的ICD诱导和增强癌症免疫治疗.
- 通过瘤特定向和酶响应度来克服当前ICD策略的局限性.
- 调查PSK在触发ICD和减少瘤免疫逃脱中的双作用机制.
主要方法:
- 设计了一种 (PSK),可以在瘤细胞上选择性地与PD-L1结合,以增强吸收.
- 在TME中利用木素酶来催化PSK自组合成纳米聚合物,以长时间保留瘤.
- 研究了PSK的线粒体向,以精确的器官水平作用和ICD诱导.
主要成果:
- 通过破坏线粒体膜潜能和诱导ICD,PSK显示出协同作用的抗瘤效应.
- PSK触发了损伤相关分子模式 (DAMPs) 的释放,激活了抗瘤免疫力.
- PSK有效地降低了PD-L1的表达,减少了瘤免疫逃逸,具有高瘤选择性和没有显著的全身毒性.
结论:
- PSK代表了一种有前途的酶响应,自我组装的类药物,用于精确的瘤治疗.
- PSK的双作用机制解决了基于ICD的癌症免疫治疗中的关键挑战.
- PSK为开发向抗癌类药物提供了一种新的方法.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Translocation of Proteins into the Mitochondria
11.9K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
11.9K
Mitochondrial Precursor Proteins
3.5K
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...
Most of the mitochondrial...
3.5K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


